Pharmaceutical company Dr Reddy's Laboratories Limited (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Saturday announced the divestiture of its US and select territory rights for ZEMBRACE SYMTOUCH (sumatriptan injection) in 3 mg and TOSYMRA (sumatriptan nasal spray) in 10 mg to Upsher-Smith Laboratories LLC.
17 June 2019 - Minnesota, US-based pharmaceutical company Upsher-Smith Laboratories, LLC has agreed to acquire US and other territory rights for two migraine treatments: Tosymra (sumatriptan nasal spray) 10 mg and ZembraceSymTouch (sumatriptan injection) 3 mg from India-based Dr.
In the United States only subcutaneous sumatriptan injections and intravenous DHE are approved for acute use, however, DHE is limited to hospital use and the FDA approved labeling for sumatriptan allows a maximum of two doses per day.
THE FOOD AND DRUG Administration is evaluating patient reports of serious burns and potential permanent scarring that have occurred with the use of the Zecuity patch (sumatriptan iontophoretic transdermal system) to relieve migraine headaches.
The recommended dose for pediatric patients (12 years and older) is a single tablet of Treximet 10/60 mg (sumatriptan 10 mg and naproxen sodium 60 mg) per 24 hours; the maximum recommended dose is 85/500 mg per 24 hours.
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.